A PHP Error was encountered

Severity: 8192

Message: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated

Filename: helpers/my_audit_helper.php

Line Number: 8900

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 8900
Function: str_replace

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3362
Function: formatAIDetailSummary

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Murine immune responses to oral BCG immunization in the presence or absence of prior BCG sensitization. | LitMetric

Oral delivery of live Mycobacterium bovis BCG in a lipid matrix invokes cell-mediated immune (CMI) responses in mice and consequent protection against pulmonary challenge with virulent mycobacteria. To investigate the influence of prior BCG sensitization on oral vaccine efficacy, we assessed CMI responses and BCG colonization of the alimentary tract lymphatics 5 months after oral vaccination, in both previously naive mice and in mice that had been sensitized to BCG by injection 6 months previously. CMI responses did not differ significantly between mice that received subcutaneous BCG followed by oral BCG and those that received either injected or oral BCG alone. In vivo BCG colonization was predominant in the mesenteric lymph nodes after oral vaccination; this colonizing ability was not influenced by prior BCG sensitization. From this murine model study, we conclude that although prior parenteral-route BCG sensitization does not detrimentally affect BCG colonization after oral vaccination, there is no significant immune-boosting effect of the oral vaccine either.

Download full-text PDF

Source
http://dx.doi.org/10.1038/icb.2009.85DOI Listing

Publication Analysis

Top Keywords

bcg sensitization
16
bcg
13
oral bcg
12
prior bcg
12
cmi responses
12
bcg colonization
12
oral vaccination
12
oral
9
sensitization oral
8
oral vaccine
8

Similar Publications

Field Trial with Vaccine Candidates Against Bovine Tuberculosis Among Likely Infected Cattle in a Natural Transmission Setting.

Vaccines (Basel)

October 2024

Instituto de Agrobiotecnología y Biología Molecular (IABiMo), UEDD CONICET-INTA, Centro de Investigación en Ciencias Veterinarias y Agronómicas (CICVyA)-CNIA, Hurlingham 1686, Buenos Aires Province, Argentina.

Article Synopsis
  • * In a trial, 74 heifers were vaccinated with different strains and then exposed to naturally infected animals, but the initial vaccination did not produce an adequate immune response, and re-vaccination did not show significant protection against the disease.
  • * The study found a 23% transmission of wild-style strains in non-vaccinated animals, and while some vaccine candidates showed promise in reducing lesions, overall results indicated that further evaluation is needed, as current vaccines did not ensure improved outcomes.
View Article and Find Full Text PDF

Neonatal BCG Vaccination for Prevention of Allergy in Infants: The MIS BAIR Randomised Controlled Trial.

Clin Exp Allergy

September 2024

Infectious Diseases, Clinical Epidemiology & Biostatistics Unit, Population Allergy, Murdoch Children's Research Institute, Parkville, Victoria, Australia.

Background: The beneficial off-target effects of Bacille Calmette-Guérin (BCG) vaccination potentially include protection against allergy.

Objective: In the MIS BAIR trial, we aimed to determine whether neonatal BCG vaccination reduces atopic sensitisation and clinical food allergy in infants.

Methods: In this randomised controlled trial, 1272 neonates were allocated to BCG-Denmark vaccine (0.

View Article and Find Full Text PDF

Radical cystectomy with pelvic lymph node dissection and urinary diversion is the standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). However, many patients are unwilling or unable to undergo such major surgery associated with high morbidity and a negative impact on quality of life. Chemoradiotherapy is an established treatment option for muscle-invasive bladder cancer.

View Article and Find Full Text PDF

BCG induced lower urinary tract symptoms during treatment for NMIBC-Mechanisms and management strategies.

Front Neurosci

January 2024

College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University, Bedford Park, SA, Australia.

Non-muscle invasive bladder cancer (NMIBC) accounts for ~70-75% of total bladder cancer tumors and requires effective early intervention to avert progression. The cornerstone of high-risk NMIBC treatment involves trans-urethral resection of the tumor followed by intravesical Bacillus Calmette-Guerin (BCG) immunotherapy. However, BCG therapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including urinary urgency, urinary frequency, dysuria, and pelvic pain which can undermine treatment adherence and clinical outcomes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!